AOD-9604 Medicaid Coverage by State Tier

Why AOD-9604 Is Not on Any Medicaid Formulary

AOD-9604 does not qualify for Medicaid reimbursement in any state because federal Medicaid statute (42 U.S.C. § 1396r-8) requires drugs to hold FDA approval before a state can reimburse them through its formulary. AOD-9604 has never received an FDA New Drug Application (NDA) approval, a Biologics License Application (BLA) approval, or an Abbreviated New Drug Application (ANDA) approval. The FDA's searchable drug database confirms no approved application exists for AOD-9604 as of January 2026.

This is a federal ceiling, not a state-by-state discretionary choice. Even states with the most expansive Medicaid benefits, California's Medi-Cal, New York's Medicaid, or Illinois's Medicaid, cannot add an unapproved compound to their formularies without violating federal matching-fund rules.

The Federal Medicaid Drug Coverage Rule

The Social Security Act requires that a covered outpatient drug must be a product with a valid FDA approval and a rebate agreement with CMS [1]. Compounded preparations, by definition, fall outside this framework. The FDA distinguishes between FDA-approved drugs and compounded preparations explicitly, noting that compounded drugs "are not FDA-approved" and have not undergone the agency's premarket review for safety, efficacy, and quality [2].

AOD-9604 is compounded at state-licensed 503A pharmacies, patient-specific compounding operations regulated under the Drug Quality and Security Act of 2013 [3]. Products from 503A pharmacies cannot be submitted for CMS rebate agreements. No rebate agreement means no Medicaid reimbursement.

Why 503B Outsourcing Facilities Do Not Help Here Either

Some compounded drugs from 503B outsourcing facilities (large-scale, FDA-registered operations) may qualify for limited federal procurement programs. AOD-9604 is not on the FDA's list of bulk drug substances nominated for 503B compounding, meaning no 503B facility may legally compound it for general distribution [4]. The drug therefore has no route into any government payer system in its current regulatory state.

State-by-State Medicaid Tier Analysis for AOD-9604

Every state Medicaid program uses a tiered formulary, the specific tiers and co-pay structures vary, but the outcome for AOD-9604 is identical across all tiers in all 50 states: not covered.

The table below shows how several high-population states categorize the drug and what alternatives those programs do cover for weight management.

| State | Medicaid Program | AOD-9604 Coverage | Covered Weight-Loss Rx | |---|---|---|---| | California | Medi-Cal | Not covered | Orlistat (generic) | | Texas | Texas Medicaid | Not covered | None (obesity drugs excluded) | | Florida | Florida Medicaid | Not covered | None (obesity drugs excluded) | | New York | NY Medicaid | Not covered | Orlistat; semaglutide (select plans, 2025) | | Illinois | Illinois Medicaid | Not covered | Orlistat | | Washington | Apple Health | Not covered | Semaglutide 2.4 mg (2024 expansion) | | Colorado | Health First Colorado | Not covered | Semaglutide 2.4 mg (2025 expansion) | | Massachusetts | MassHealth | Not covered | Orlistat; bupropion/naltrexone (selected) |

States That Have Expanded GLP-1 Coverage: The Contrast

Washington, Colorado, and a growing number of states have extended Medicaid coverage to FDA-approved GLP-1 receptor agonists for obesity. Washington State's Apple Health began covering semaglutide 2.4 mg (Wegovy) for members with a BMI ≥30 or a BMI ≥27 with a weight-related comorbidity in 2024. That expansion was possible precisely because semaglutide holds an FDA approval (NDA 215256) and Novo Nordisk maintains a CMS rebate agreement.

AOD-9604 cannot follow that same path without completing a full Phase III program, submitting an NDA, receiving FDA approval, and negotiating a CMS rebate. None of those steps are in progress as of 2026.

Medicare Part D: The Same Answer

Medicare Part D specifically excludes weight-loss drugs from standard coverage under 42 U.S.C. § 1395w-102(e)(2)(A), though the Inflation Reduction Act and subsequent regulatory guidance have opened limited exceptions for FDA-approved anti-obesity medications tied to cardiovascular risk reduction [5]. AOD-9604 qualifies for none of these exceptions. Patients over 65 face the same zero-coverage outcome as Medicaid beneficiaries.

What the Clinical Evidence Says About AOD-9604

Understanding the coverage gap requires understanding exactly where AOD-9604 sits in the development pipeline. It is not a fringe or theoretical compound. It has completed Phase II human trials. But it has not cleared the bar that FDA and CMS require.

Phase II Trial Data

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176-191 of human growth hormone (hGH). It was developed by Metabolic Pharmaceuticals (Melbourne, Australia) with a primary focus on fat reduction without the diabetogenic effects of full-length hGH. A Phase IIb randomized controlled trial (N=300) published in 2004 evaluated five oral doses of AOD-9604 against placebo over 12 weeks [6]. The 1 mg daily dose group lost a mean of 2.6 kg versus 0.8 kg for placebo, a statistically significant difference at that dose (P<0.01). No Phase III trial followed. Metabolic Pharmaceuticals discontinued the obesity program after the Phase IIb results were deemed commercially insufficient.

No Approved Indication Exists

Because no Phase III data were submitted and no NDA was filed, AOD-9604 has no FDA-recognized indication, not for obesity, lipodystrophy, osteoarthritis (a secondary target explored in later research), or any other condition [7]. The FDA's GRASE (Generally Recognized as Safe and Effective) status does not apply. The compound exists in the same regulatory space as other research peptides: legal to prescribe off-label as a compounded preparation for individual patients in states where that is permitted, but not available through any insurance reimbursement pathway.

The HealthRX Coverage Readiness Framework scores any compound on four criteria before a coverage claim can be made: (1) FDA approval status, (2) active CMS rebate agreement, (3) state formulary committee review, and (4) peer-reviewed Phase III safety data. AOD-9604 scores 0 of 4. Any telehealth platform or pharmacy claiming that AOD-9604 "may be covered" by Medicaid or Medicare is making a claim that is not supported by current law or payer policy.

How to Get AOD-9604 Cheaper: Legal Cost-Reduction Strategies

Because insurance does not apply, patients pay compounding pharmacy list prices directly. Typical monthly costs for injectable AOD-9604 range from $150 to $350, depending on dose, frequency, and pharmacy. Several strategies can reduce that out-of-pocket burden.

HSA and FSA Accounts

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cover prescription medical expenses that are prescribed by a licensed provider for a diagnosed medical condition [8]. AOD-9604 ordered through a compounding pharmacy with a valid prescription from a licensed physician qualifies as a prescription drug expense. The IRS definition of a qualified medical expense (Publication 502) includes "prescription medicine or drugs" without restricting coverage to FDA-approved drugs.

A patient with a $3,000 HSA balance paying 25% marginal federal income tax saves approximately $750 per year in taxes by routing AOD-9604 purchases through the HSA rather than paying with after-tax dollars. FSA rules are similar, though use-it-or-lose-it provisions apply to most FSA plans.

To use HSA/FSA for AOD-9604: obtain a dated prescription from a licensed prescriber listing the diagnosis, drug name, dose, and quantity. Submit the compounding pharmacy receipt and prescription to your HSA/FSA administrator. Most major HSA administrators (Fidelity, HealthEquity, WEX) process compounded prescription claims without issue when documentation is complete.

Telehealth Platform Pricing vs. Direct Pharmacy Pricing

Telehealth platforms that offer peptide prescribing typically bundle the consultation fee and the medication into a monthly subscription. Prices cluster around $200, $299 per month, which includes clinical oversight. Patients who already have a prescribing provider may obtain the prescription independently and use a direct compounding pharmacy, which may reduce costs to $150, $200 per month. The tradeoff is the loss of bundled clinical monitoring.

Clinical Trial Enrollment

ClinicalTrials.gov listed two active or recently completed trials involving AOD-9604 variants as of late 2025, primarily investigating cartilage repair applications. Participants in drug-arm trials receive the study compound at no cost. Eligibility requirements narrow the pool significantly, but enrollment is worth checking for patients who also have osteoarthritis or metabolic conditions that match ongoing protocols.

Manufacturer Patient Assistance: Not Applicable

Traditional pharmaceutical patient assistance programs (PAPs) exist for branded FDA-approved drugs. Because AOD-9604 is compounded, no manufacturer PAP applies. There is no Novo Nordisk-style savings card or copay coupon for a 503A-compounded peptide. Discount platforms like GoodRx also do not apply because those platforms work within the FDA-approved drug supply chain.

Comparing AOD-9604 Costs Against Covered Alternatives

Patients considering AOD-9604 for weight management should weigh the cost against FDA-approved alternatives that may carry insurance coverage.

| Drug | FDA Approval | Average Monthly OOP (Uninsured) | Medicaid Coverage | |---|---|---|---| | AOD-9604 (compounded) | None | $150, $350 | None (all states) | | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | $1,349 list; $0, $25 with coverage | 19 states as of 2026 | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | $1,059 list; varies with coverage | 7 states as of 2026 | | Orlistat 120 mg (generic) | Yes (1999) | $30, $60 | Most states | | Bupropion/naltrexone (Contrave) | Yes (2014) | $20, $60 generic | Selected states |

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [9]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks versus 2.4% with placebo (P<0.001) [10]. AOD-9604 has no equivalent Phase III dataset. Patients weighing clinical efficacy against cost must account for the substantial efficacy gap between current Phase IIb AOD-9604 data and the Phase III evidence behind approved GLP-1 therapies.

What Providers Need to Know When Prescribing AOD-9604

Physicians and nurse practitioners prescribing AOD-9604 through a 503A compounding pharmacy bear responsibility for documenting the clinical rationale under the "valid prescription" standard. The Endocrine Society's 2024 obesity pharmacotherapy guidelines do not mention AOD-9604 due to the absence of Phase III data [11]. Providers should document informed consent specifically noting that:

• AOD-9604 is not FDA-approved.
• No insurance reimbursement is available.
• Long-term safety data are limited to Phase II duration.
• Off-label compounded prescribing is legally permitted but not guideline-endorsed.

The FDA has not placed AOD-9604 on any list of drugs that may not be compounded (the "Category 1" or "Category 2" lists under 503A restrictions). Its absence from those restriction lists means compounding is currently legal, but that status can change if FDA receives safety signals or takes regulatory action [12].

As the Endocrine Society stated in their 2024 clinical practice guideline: "Pharmacological therapy should be offered alongside lifestyle intervention for patients with obesity, using agents with established safety and efficacy profiles from randomized controlled trials" [11]. AOD-9604 does not yet meet that standard.

State Medicaid Policy Trends to Watch in 2026 and Beyond

Three policy developments could eventually affect how state Medicaid programs approach peptide compounds.

CMS Obesity Drug Expansion

The Biden administration proposed a rule in November 2023 to allow Medicare Part D and Medicaid to cover FDA-approved anti-obesity medications more broadly. That rule applies only to FDA-approved drugs. If AOD-9604 eventually obtains FDA approval, CMS expansion rules would create a pathway. That pathway does not exist today.

State Bulk Purchasing Programs

Several states, including California and Washington, have established prescription drug affordability boards that negotiate directly with manufacturers or contract with 503B outsourcing facilities for selected compounds. None of these programs have included research peptides like AOD-9604 as of 2026. California's CalRx bulk purchasing initiative targets generic versions of FDA-approved drugs, not compounded research peptides.

FDA Bulk Drug Substance Nominations

The FDA periodically reviews nominations to add compounds to the 503A or 503B bulk drug substance lists. If AOD-9604 were nominated and approved for the 503B list, outsourcing facilities could compound it at scale for institutional use. Even that step would not create insurance coverage, but it might improve quality standardization and reduce per-unit costs. No active nomination for AOD-9604 appears on the FDA's current review list.

Practical Steps for Patients in 2026

Patients who have decided to pursue AOD-9604 and want to minimize cost without misunderstanding the coverage field should take these specific actions:

1. Get a dated prescription from a licensed provider in your state with a documented diagnosis. Without this, HSA/FSA reimbursement is unavailable.
2. Use your HSA or FSA to pay the compounding pharmacy invoice. Keep the receipt and prescription together for at least three years in case of audit.
3. Compare telehealth bundles vs. Direct pharmacy pricing before committing to a platform. Ask each vendor whether their quoted price includes the clinical consultation or just the compound.
4. Check ClinicalTrials.gov (clinicaltrials.gov) quarterly for new AOD-9604 trials if you qualify by age, BMI, or comorbidity profile.
5. Do not expect coverage changes in the near term. No state has signaled an intent to create a special coverage category for research peptides in 2026 legislative sessions reviewed by the HealthRX policy team.
6. Discuss FDA-approved alternatives with your provider. If semaglutide or tirzepatide are clinically appropriate and your state Medicaid program covers them, the net cost and efficacy profile of those agents may outperform AOD-9604 for weight management specifically.